Quality of Life, Depression, Sexual Dysfunction and Work Absenteeism in Relapsing-Remitting Multiple Sclerosis Patients Starting Glatiramer Acetate as First-Line Treatment: A Prospective Cohort Study

4CPS-138 Quality of life in multiple sclerosis patients with parenteral first-line treatment: experience in a university hospital

10.1136/ejhpharm-2018-eahpconf.229 ◽

2018 ◽

Author(s):

S Oprea ◽

S Negres

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

University Hospital ◽

Line Treatment ◽

First Line ◽

Treatment Experience ◽

Relapsing Remitting Multiple Sclerosis Patients Initiated on Oral Dmf Report A Better Quality of Life Compared to Patients on Platform Therapies As Measured By Eq-5d

Value in Health ◽

10.1016/j.jval.2015.09.2492 ◽

2015 ◽

Vol 18 (7) ◽

pp. A762

Author(s):

R Iyer ◽

E Jones ◽

J Rana ◽

J Petrillo ◽

A Lee ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Relapsing Remitting ◽

Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex

Journal of Research in Pharmacy Practice ◽

10.4103/2279-042x.185725 ◽

2016 ◽

Vol 5 (3) ◽

pp. 181 ◽

Cited By ~ 3

Author(s):

Nahid Hatam ◽

Peivand Bastani ◽

RahilSadat Shahtaheri

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Relapsing Remitting ◽

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2009.15.7.543 ◽

2009 ◽

Vol 15 (7) ◽

pp. 543-555 ◽

Cited By ~ 15

Author(s):

Lawrence Goldberg ◽

Natalie C. Edwards ◽

Contessa Fincher ◽

Quan V. Doan ◽

Ahmad AL-Sabbagh ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Line Treatment ◽

First Line ◽

Disease Modifying Drugs ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis

Journal of Clinical Neuroscience ◽

10.1016/j.jocn.2015.12.044 ◽

2016 ◽

Vol 33 ◽

pp. 73-78 ◽

Cited By ~ 5

Author(s):

Inês Correia ◽

Inês Brás Marques ◽

Mário Sousa ◽

Sónia Batista ◽

Rogério Ferreira ◽

...

Keyword(s):

Multiple Sclerosis ◽

Line Treatment ◽

First Line ◽

Treatment Persistence ◽

Relapsing Remitting ◽

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(12)61769-3 ◽

2012 ◽

Vol 380 (9856) ◽

pp. 1819-1828 ◽

Cited By ~ 688

Author(s):

Jeffrey A Cohen ◽

Alasdair J Coles ◽

Douglas L Arnold ◽

Christian Confavreux ◽

Edward J Fox ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Relapsing Remitting ◽

Randomised Controlled ◽

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Health and Quality of Life Outcomes ◽

10.1186/1477-7525-8-133 ◽

2010 ◽

Vol 8 (1) ◽

pp. 133 ◽

Cited By ~ 30

Author(s):

Peter J Jongen ◽

Dirk Lehnick ◽

Evert Sanders ◽

Pierrette Seeldrayers ◽

Sten Fredrikson ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Health Related Quality ◽

Multi Centre Study ◽

Relapsing Remitting ◽

Related Quality ◽

Health Related ◽

The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: a randomized clinical trial

International Journal of Neuroscience ◽

10.1080/00207454.2020.1750398 ◽

2020 ◽

pp. 1-9

Author(s):

Zahra Mousavi-Shirazi-Fard ◽

Zohreh Mazloom ◽

Sadegh Izadi ◽

Mohammad Fararouei

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Inflammatory Biomarkers ◽

Relapsing Remitting ◽

Faculty Opinions recommendation of Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964602.793468851 ◽

2013 ◽

Author(s):

Giancarlo Comi

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Relapsing Remitting ◽

Randomised Controlled ◽

PND11 Budget Impact Analysis of First-Line Treatment for Relapsing – Remitting Multiple Sclerosis in Spain

Value in Health ◽

10.1016/j.jval.2011.08.477 ◽

2011 ◽

Vol 14 (7) ◽

pp. A319 ◽

Cited By ~ 1

Author(s):

R. Sánchez-de la Rosa ◽

E. Sabater ◽

M.A. Casado

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Line Treatment ◽

First Line ◽

Relapsing Remitting ◽